$58.96+10.41% · 3M
Moving avg
1W+3.86%
1M+4.71%
3M+11.56%
6M+30.47%
YTD+51.72%
1Y+61.54%
3Y+95.82%
5Y+54.14%
52-week range
$34.0897% of range$59.72
Company health
Value1/6
Growth2/6
Profitability6/6
Health1/6
Dividend4/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- Strong 32% net margin
- High return on equity (1267%)
Risks
No obvious red flags from the metrics.
Key statistics
Valuation
Market cap
$26.14B
Enterprise value
$33.59B
P/E ratio (TTM)
23.80x
P/S ratio (TTM)
10.33x
EV/EBITDA
19.77x
Per share & returns
EPS (TTM)
$1.92
Dividend yield
1.55%
Beta (1Y)
0.42
30-day change
+4.71%
Trading
Volume (24h)
607.52K
Previous close
$59.22
Shares outstanding
443.27M
About Royalty Pharma plc
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Symbol
RPRX
Royalty Pharma plc is a large-cap healthcare company in the Medical - Pharmaceuticals industry. Its shares are listed on NASDAQ (United States) and trade under the ticker RPRX.
Frequently asked questions
What is Royalty Pharma plc's market cap?
Royalty Pharma plc (RPRX) has a market capitalization of $26.14B.
What is Royalty Pharma plc's P/E ratio?
Royalty Pharma plc trades at a price-to-earnings (P/E) ratio of 23.80.
What exchange does RPRX trade on?
RPRX trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,218.39-0.15%
$1.15T cap
Johnson & JohnsonJNJ
$261.39+0.20%
$629.92B cap
AbbVie Inc.ABBV
$250.32+0.63%
$442.26B cap
UnitedHealth Group IncorporatedUNH
$402.17-0.84%
$365.22B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.77+1.39%
$332.86B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.76B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap